Hydroalcoholic extract of Benincasa hispida (Thunb.) Cogn. reinstates renal structural and functional dynamics...

Benincasa hispida possess substantial ethnopharmacological value across traditional medicines in Asia. It has been used traditionally for the management of various pathological conditions, including obesity, ulcers, epilepsy, bleeding piles, hyperacidity, haemoptysis, dysuria, and urinary calculi. Preclinical studies have demonstrated its nephroprotective potential in rodent models of acute and sub-chronic toxicity. However, its potential pharmacological targets and mechanisms underlying the ethnopharmacological aspects remains to be elucidated.

The present study aims to elucidate the molecular mechanisms by which Benincasa hispida confers the protection against diabetic nephrotoxicity, primarily through modulation of hyperglycaemia-induced renal fibrosis and prevention of podocytes loss, specialized glomerular cells essential for maintaining the integrity of the filtration barrier.

UHPLC-Q-Orbitrap HRMS was employed to characterize the phytochemical composition of the hydroalcoholic extract of Benincasa hispida. Its pharmacological effects were investigated in a mouse model of type 2 diabetes, which was developed through a high-fat diet with low doses of streptozotocin. The analyses included a comprehensive evaluation of the extract's impact on serum biochemical parameters, as well as the identification of key genes and proteins involved in kidney function, using integrative transcriptomics, proteomics, qPCR, and immunohistochemical methods.

LC-HRMS analysis identified 28 phytochemicals in the hydroalcoholic extract ofBenincasa hispida, predominantly belonging to the category of flavonoids, phenolics, triterpenoids, cucurbitacins, sterol glycosides, coumarins, and related compounds. The presence of catechin, naringenin, kaempferol, cucurbitacin E, cucurbitacin I, dihydrocucurbitacin B, quercetin, myricetin, 3-hydroxyflavone, etc., demonstrates Benincasa hispida as a valuable source of bioactive molecules. Blood serum of mice on a high-fat diet showed elevated glucose, triglycerides, total protein, urea, and cholesterol, and decreased creatinine, indicating metabolic dysregulation and chronic diabetic state. Treatment with Benincasa hispida extract significantly restored these biochemical parameters to near normal levels. In-depth integrated proteomics and transcriptomics analysis revealed differential expression of genes and proteins involved in cytoskeletal organisation, vesicle transport systems, extracellular matrix, and cell-cell adhesion in the kidneys of diabetic mice. Consistently, diabetic mice exhibited a marked reduction in podocytes, as evidenced by the downregulation of gene expression specific to the podocyte cytoskeleton genes (cd2ap, actn4, and podxl), which are essential for maintaining glomerular filtration integrity. A significant increase in core histone proteins identified through proteomics has revealed genotoxicity and chromatin remodelling in diabetic mice. Immunohistochemical analysis of PARP1, H2AX, HDAC1, 5'-MC, TET1, and 5'-HMC proteins confirmed DNA damage and epigenetic alterations in the kidneys of diabetic mice. Administration of Benincasa hispida extract effectively repaired DNA damage, restored epigenetic homeostasis, and mitigated podocyte loss. Furthermore, treatment with the extract significantly reduced renal inflammation and fibrosis by modulating key inflammatory and profibrotic mediators, such as CD200, TGF-β, and BCl3, which were activated under hyperglycemic condition. In this study, we identified three potential renal cell type-specific targets (S100A6, ACSM2, and TPD52) for the therapeutic action of Benincasa hispida extract, warranting future validation.

The results of our investigation provide a scientific basis for the nephroprotective properties of Benincasa hispida in a mouse model of type 2 diabetes. The observed effects were associated with decreased genotoxicity and renal fibrosis, along with improved podocyte function.